Methods for Detecting AAV Particles

Patent Number: 12,123,880 B2
Assignee: Genzyme Corporation (Sanofi subsidiary)
Issue (Grant) Date: October 22, 2024
Relevance to Sarepta: Asserted against Sarepta in patent litigation over its Elevidys® Duchenne muscular dystrophy (DMD) gene therapy.

What This Patent Covers

While Sarepta itself doesn’t own this patent, Patent No. 12,123,880 has been legally significant and directly tied to Sarepta’s commercial gene therapy product:

Core invention:

It claims **methods for detecting and characterizing adeno‑associated virus (AAV) particles used in **gene therapy vector formulations.
These methods typically involve analytical techniques such as denaturation of viral particles followed by liquid chromatography–mass spectrometry (LC/MS) analysis or related approaches to measure viral protein characteristics. These analyses are central to quality control for AAV‑based gene therapy products like Elevidys®.

Why it matters in the context of Sarepta:

Genzyme (Sanofi) asserted this patent (among others such as U.S. Patents Nos. 12,031,894 and 12,298,313) against Sarepta in a Delaware federal lawsuit alleging that Sarepta’s manufacture and sale of Elevidys® infringes these patented analytical methods.
Because accurate characterization of vector capsid proteins and particle consistency is required for regulatory release of commercial AAV gene therapies, this patent strikes at a critical part of the drug supply chain and quality control.

Example claim language (methods):

Operations like denaturing AAV particles,
Performing intact protein analysis with LC/MS, and
Determining the masses of viral proteins without gel separation — all central to confirming vector integrity during manufacturing and release testing.

Why This Patent Is Important

Commercial stake: Elevidys® is one of Sarepta’s major revenue‑generating products, approved for DMD (a severe muscle‑wasting disease). Allegations that it infringes foundational vector‑analysis patents have material financial and operational implications for the company’s business.
Litigation leverage: The patent’s assertion in court could lead to damages, injunctions, or royalty obligations, affecting Elevidys®’s profitability — reported to bring hundreds of millions in revenue for Sarepta.
Regulatory and manufacturing impact: Methods covered by this patent relate to routine release testing of AAV gene therapy products; if enforced, Sarepta might need licensing agreements or change analytical workflows to comply.

Summary

While Sarepta may not own this specific patent, U.S. Patent No. 12,123,880 — titled Methods for Detecting AAV Particles and issued October 22, 2024 — was among the most important patents affecting Sarepta because it was aggressively asserted against the company in litigation over its Elevidys® gene therapy. The patent claims analytical methods critical for quality control of AAV vector products in gene therapy, positioning it at the intersection of regulatory compliance, commercial manufacturing, and legal risk for one of Sarepta’s flagship products.

BioTech IP Review